SCHEMBL8557085

SCHEMBL8557085

Cc1cc2nncn2nc1Cl

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.48
MAPT P10636 1/20 0.43
LMNA P02545 2/20 0.41
PKM P14618 1/20 0.41
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.38
GAA P10253 1/20 0.37
ALDH1A1 P00352 5/20 0.35
MAPK1 P28482 1/20 0.35
BRD4 O60885 1/20 0.35
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ADRB2 P07550 1/20 0.32
KCNH2 Q12809 1/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
CTSS P25774 1/20 0.32
RXFP1 Q9HBX9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25153033 0.73 KDM4E (0.44) KDM4EMAPTLMNAPKMHTT
SCHEMBL11473765 0.70 ALDH1A1 (0.48) KDM4EMAPTLMNAPKMHTT
SCHEMBL10998016 0.70 ALDH1A1 (0.51) KDM4EMAPTLMNAPKMHTT
SCHEMBL19327480 0.69 HTT (0.38) KDM4EMAPTHTTSMN1; SMN2ALDH1A1
SCHEMBL11487030 0.68 ALDH1A1 (0.41) KDM4EMAPTLMNAPKMHTT
SCHEMBL10994562 0.67 MET (0.46) KDM4EMAPTHTTSMN1; SMN2GAA
SCHEMBL10996935 0.67 RXFP1 (0.43) KDM4EMAPTLMNAHTTSMN1; SMN2
SCHEMBL14832909 0.67 KDM4E (0.53) KDM4ESMN1; SMN2ALDH1A1HSD17B10KMT2A
SCHEMBL11626618 0.66 KDM4E (0.49) KDM4EMAPTLMNAPKMSMN1; SMN2
SCHEMBL1426882 0.65 KDM4E (1.00) KDM4EMAPTLMNAPKMHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002507-A1 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS VANDERBILT UNIVERSITY 2025-01-02 US disclosed
WO-2023064584-A1 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS VANDERBILT UNIVERSITY (US) 2023-04-20 WO disclosed
EP-2760866-A1 DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS Genfit (FR) 2014-08-06 EP disclosed
WO-2013045519-A1 DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS GENFIT (FR) 2013-04-04 WO disclosed
EP-0620224-B1 Triazolopyridazine derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1998-07-15 EP disclosed
US-5492909-A ANTI-PLATELET ACTIVATING FACTOR, ANTIALLERGEN, ANTIASTHMATIC TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-02-20 US disclosed
EP-0620224-A1 Triazolopyridazine derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-10-19 EP disclosed
US-4526890-A Respiratory system disorders THE DOW CHEMICAL COMPANY (US) 1985-07-02 US disclosed
EP-0029130-A1 3,6,7,8-Substituted-s-triazolo(4,3-b)-pyridazines, their preparation and compositions comprising them THE DOW CHEMICAL COMPANY (US) 1981-05-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002507-A1 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS CHRM4, CHRM1, CHRM2 KDM4E 2148/4885MAPT 2346/4885LMNA 3521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.